ATE361368T1 - Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion - Google Patents
Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektionInfo
- Publication number
- ATE361368T1 ATE361368T1 AT98942413T AT98942413T ATE361368T1 AT E361368 T1 ATE361368 T1 AT E361368T1 AT 98942413 T AT98942413 T AT 98942413T AT 98942413 T AT98942413 T AT 98942413T AT E361368 T1 ATE361368 T1 AT E361368T1
- Authority
- AT
- Austria
- Prior art keywords
- vector
- protein
- host
- alphavirus
- rsv
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 2
- 241000710929 Alphavirus Species 0.000 abstract 2
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 108700010867 paramyxovirus proteins Proteins 0.000 abstract 1
- 239000013600 plasmid vector Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/923,558 US6060308A (en) | 1997-09-04 | 1997-09-04 | RNA respiratory syncytial virus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361368T1 true ATE361368T1 (de) | 2007-05-15 |
Family
ID=25448878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98942413T ATE361368T1 (de) | 1997-09-04 | 1998-09-03 | Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6060308A (de) |
| EP (1) | EP1009846B1 (de) |
| JP (1) | JP2001514857A (de) |
| AT (1) | ATE361368T1 (de) |
| AU (1) | AU742046B2 (de) |
| BR (1) | BR9815642B1 (de) |
| CA (1) | CA2301891C (de) |
| DE (1) | DE69837708T2 (de) |
| WO (1) | WO1999011808A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US7465574B2 (en) * | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US20030054505A1 (en) * | 1997-09-26 | 2003-03-20 | Hong Jin | Recombinant rsv expression systems and vaccines |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| US6830748B1 (en) * | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
| US6475780B1 (en) * | 1997-11-14 | 2002-11-05 | Aventis Pasteur Limited | Alphavirus vectors for paramyxovirus vaccines |
| EP1707633A1 (de) * | 1997-11-14 | 2006-10-04 | Sanofi Pasteur Limited | Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| DK1285080T3 (da) | 2000-05-31 | 2008-12-01 | Novartis Vaccines & Diagnostic | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
| KR100481879B1 (ko) * | 2001-02-08 | 2005-04-11 | 크레아젠 주식회사 | (+)-단일쇄 ｒｎａ 재조합 벡터내 삽입 서열의 유전적 안정성을 증가시키는 방법 |
| WO2006078294A2 (en) | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
| JP2011519828A (ja) * | 2008-04-18 | 2011-07-14 | バクシネート コーポレーション | フラジェリンの欠失変異体と使用方法 |
| EP2367844A4 (de) * | 2008-11-18 | 2012-08-01 | Ligocyte Pharmaceuticals Inc | Rsv-f-vlp und herstellungs- sowie verwendungsverfahren dafür |
| MA33449B1 (fr) * | 2009-06-24 | 2012-07-03 | Glaxosmithkline Biolog Sa | Antigènes recombinants du vrs |
| EP3988115A3 (de) | 2009-07-15 | 2022-08-17 | GlaxoSmithKline Biologicals S.A. | Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| US9801897B2 (en) | 2010-07-06 | 2017-10-31 | Glaxosmithkline Biologicals Sa | Delivery of RNA to trigger multiple immune pathways |
| CN106421773A (zh) | 2010-07-06 | 2017-02-22 | 诺华股份有限公司 | 自我复制rna分子的病毒样递送颗粒 |
| DK2590626T3 (en) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biolog Sa | Liposomes with lipids having a favorable pKa of RNA for bringing |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| DK4066856T3 (da) | 2010-08-31 | 2022-12-19 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til afgivelse af immunogen-kodende RNA |
| US20140030292A1 (en) | 2010-10-11 | 2014-01-30 | Novartis Ag | Antigen delivery platforms |
| LT2707385T (lt) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Iš anksto sulieti rsv f antigenai |
| DK3586861T3 (da) | 2011-06-08 | 2022-04-25 | Translate Bio Inc | Lipidnanopartikelsammensætninger og fremgangsmåder til mrna-indgivelse |
| US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169628A (en) | 1988-04-22 | 1992-12-08 | The Upjohn Company | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| WO1996017072A2 (en) * | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5614372A (en) * | 1995-02-24 | 1997-03-25 | Lilja; Hans | Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1) |
| US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| US6060308A (en) * | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
-
1997
- 1997-09-04 US US08/923,558 patent/US6060308A/en not_active Expired - Lifetime
-
1998
- 1998-09-03 AT AT98942413T patent/ATE361368T1/de not_active IP Right Cessation
- 1998-09-03 EP EP98942413A patent/EP1009846B1/de not_active Expired - Lifetime
- 1998-09-03 JP JP2000508816A patent/JP2001514857A/ja active Pending
- 1998-09-03 BR BRPI9815642-0B1A patent/BR9815642B1/pt not_active IP Right Cessation
- 1998-09-03 DE DE69837708T patent/DE69837708T2/de not_active Expired - Lifetime
- 1998-09-03 CA CA002301891A patent/CA2301891C/en not_active Expired - Fee Related
- 1998-09-03 WO PCT/CA1998/000840 patent/WO1999011808A1/en active IP Right Grant
- 1998-09-03 US US09/486,553 patent/US6428324B1/en not_active Expired - Fee Related
- 1998-09-03 AU AU90569/98A patent/AU742046B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR9815642B1 (pt) | 2013-09-17 |
| EP1009846B1 (de) | 2007-05-02 |
| DE69837708T2 (de) | 2008-01-10 |
| JP2001514857A (ja) | 2001-09-18 |
| WO1999011808A1 (en) | 1999-03-11 |
| AU9056998A (en) | 1999-03-22 |
| CA2301891A1 (en) | 1999-03-11 |
| BR9815642A (pt) | 2002-12-31 |
| DE69837708D1 (de) | 2007-06-14 |
| US6428324B1 (en) | 2002-08-06 |
| AU742046B2 (en) | 2001-12-13 |
| US6060308A (en) | 2000-05-09 |
| CA2301891C (en) | 2010-01-19 |
| EP1009846A1 (de) | 2000-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE361368T1 (de) | Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion | |
| Smerdou et al. | Two-helper RNA system for production of recombinant Semliki forest virus particles | |
| Chan et al. | Complete nucleotide sequences of Nipah virus isolates from Malaysia | |
| Plyusnin et al. | Sequences of wild Puumala virus genes show a correlation of genetic variation with geographic origin of the strains | |
| BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
| DK0724642T4 (da) | Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis | |
| BR9608615A (pt) | Vacinas de vírus sincicial respiratório de ácido nucléico | |
| CY1116837T1 (el) | Αλληλουχιες κυκλοϊου σχετικου με την νοσο απισχνασης του χοιριδιου (map) | |
| DE69829668D1 (de) | Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe | |
| ATE358732T1 (de) | Anti-virale vektoren | |
| WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
| BR9815285A (pt) | Vetores alfavìrus para vacina de paramixovìrus | |
| Mallipeddi et al. | Sequence comparison between the phosphoprotein mRNAs of human and bovine respiratory syncytial viruses identifies a divergent domain in the predicted protein | |
| US20160228531A1 (en) | Treatment of hepatitis d virus infections by redirection of t cells | |
| PT778894E (pt) | Vacina da peritonite infecciosa felina. | |
| Pelletier et al. | Expression of Reovirus Type 3 (Dearing) σ1 and σs Polypeptides in Escherichia coli | |
| WO2000044406A3 (en) | Dna vaccines against hantavirus infections | |
| ATE269064T1 (de) | Impfstoffe gegen den hepatitis b und c virus | |
| DE60229966D1 (de) | Diabetesmodell | |
| ES2367245T8 (es) | Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo. | |
| PT1254663E (pt) | Agente antiviral | |
| ATE476511T1 (de) | Nukleinsäuren von hdv, deren bruchstücken und deren verwendungen | |
| ATE474927T1 (de) | Schützende hochmolekulargewichtsproteine aus haemophilus influenzae | |
| CA2086577A1 (en) | Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |